scorecardresearch
Wednesday, August 20, 2025
TopicRanbaxy Laboratories

Topic: Ranbaxy Laboratories

Supreme Court holds ex-Ranbaxy promoters Malvinder & Shivinder Singh in contempt of court

The top court said that the brothers Malvinder and Shivinder Singh had violated an earlier order by which the sale of their controlling stakes in Fortis Group to Malayasian firm IHH Healthcare was put on hold.

Cases that took Malvinder, Shivinder Singh from Forbes billionaires’ list to police custody

The Singh brothers are accused of multiple cases of siphoning money using a complex web of companies, including Ranbaxy, Religare & Fortis.

How Ranbaxy faked manufacturing data for all drugs not only in India, but in US, Europe too

Ranbaxy was treating data as an entirely fungible marketing tool, apparently without consideration of impact on patients. It was an outright fraud.

The billionaires and the baba: How Fortis Healthcare founders burnt through $2 billion

Over the years, brothers Malvinder and Shivinder loaned about Rs 2,500 crore to their spiritual guru Gurvinder Singh Dhillon which they failed recover.

On Camera

New insolvency frameworks to shorter timelines, how 2025 amendment bill proposes to transform IBC

New bill aims to fix key issues with IBC 2016, including delays & patchy implementation, and protect creditors, with window for genuine promoters to retain control of their companies.

First-of-its kind tri-services conference Ran Samvad to take place in Army War College next week

Billed as the military’s own version of Raisina Dialogue, the event will spotlight on tech-driven warfighting, lessons from Operation Sindoor and release of three new doctrines.

War of IAF, PAF doctrines: As Pakistan obsesses over numbers, India embraces risk, wins

Now that both IAF and PAF have made formal claims of having shot down the other’s aircraft in the 87-hour war in May, we can ask a larger question: do such numbers really matter?